Haleon plc (LON:HLN) Receives GBX 407.83 Average Price Target from Brokerages

Shares of Haleon plc (LON:HLN) have been given an average rating of “Moderate Buy” by the six research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is GBX 407.83.

A number of equities research analysts have recently commented on HLN shares. Berenberg Bank lifted their price target on shares of Haleon from GBX 507 to GBX 517 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Royal Bank Of Canada restated a “sector perform” rating and set a GBX 370 target price on shares of Haleon in a research report on Friday, October 31st. Deutsche Bank Aktiengesellschaft cut their price target on Haleon from GBX 340 to GBX 335 and set a “buy” rating for the company in a report on Thursday. Jefferies Financial Group reissued a “buy” rating and set a GBX 450 price target on shares of Haleon in a research note on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a report on Wednesday, November 26th.

Haleon Trading Up 0.4%

Haleon stock opened at GBX 379.80 on Thursday. The stock has a 50-day moving average price of GBX 368.78 and a 200 day moving average price of GBX 359.32. Haleon has a 52 week low of GBX 325.10 and a 52 week high of GBX 419.50. The stock has a market cap of £33.83 billion, a PE ratio of 22.74, a P/E/G ratio of 1.49 and a beta of 0.19. The company has a current ratio of 0.84, a quick ratio of 0.93 and a debt-to-equity ratio of 53.36.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.